Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

For National Access To FAMILION Genetic Tests, Clinical Data Inc Signs Contract

PGxHealth, a division of Clinical Data, Inc has executed a contract with Blue Cross and Blue Shield Association (BCBSA) which will provide individual Blue Shield and Blue Cross companies with access to the FAMILION Long QT Syndrome (LQTS) genetic tests for inherited cardiac syndromes. Each of the 39 separate Blue Shield and Blue Cross companies, acting independently has the opportunity to enter into an ancillary contract to access the tests for its members, as each Blue company may deem fit. The FAMILION LQTS tests are used to detect an inherited form of cardiac disease, Long QT Syndrome. The FAMILION LQTS tests can help to guide treatment decisions and may prevent possible sudden cardiac death by detecting genetic mutations in certain individuals and their families. “This contract represents a significant achievement for PGxHealth and we look forward to working with the Blue Cross and Blue Shield companies to obtain coverage for our FAMILION tests,” said Jim Shaffer, Vice President, Sales and Marketing of PGxHealth.